Heart Failure with Preserved Ejection Fraction (HFpEF) Clinical Trials

Find Heart Failure with Preserved Ejection Fraction (HFpEF) Clinical Trials Near You

Pacemaker Implantation in Patients With Heart Failure With Preserved Ejection Fraction, Chronotropic Incompetence and Small Ventricular Volume. The SHOP-HF Trial

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This study is designed as a multicenter, prospective, controlled, randomized, two-arms, cross-over, two parallel cohorts, efficacy Clinical research with CE-marked medical device . The crossover trial will be performed in a blind fashion, so each participant will be evaluated during both blinded pacing-on and pacing-off phases, each of which will last 3 months. The population includes patients with the diagnosis of stable HFpEF according to criteria of the European Society of Cardiology and New York Heart Association (NYHA) functional class II-III/IV, left ventricular hypertrophy with small ventricular volume, sinus rhythm with low basal heart rate and chronotropic incompetence (CI). All patients will undergo pacemaker implantation, and computer-generated randomization sequence previously designed will be used to allocate participants (in a 1:1 ratio) to receive: (a) programming of the pacemaker with pacing On followed by pacing Off in two periods of 3 months; or (b) programming of the pacemaker with pacing Off followed by pacing On in two periods of 3 months. The study will be conducted in three centers in Spain. Discounting the time due to staggered entry, the total duration of a patient's follow-up will be 7 months.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Stable symptomatic heart failure (NYHA functional class ≥II) during the last month.

• Diagnosis criteria of HFpEF according to ESC guidelines:

‣ symptoms and signs of HF.

⁃ left ventricular ejection fraction ≥50% by Simpson method.

⁃ proBNP \>125 pg/mL in the last month.

⁃ at least one additional criterion: 1. relevant structural heart disease (left ventricular hypertrophy and/or left atrial enlargement); and/or 2. Diastolic dysfunction.

• Left ventricular hypertrophy was defined as wall thickness \> 10 mm.

• Small ventricular volume was defined as indexed left ventricular end diastolic volume \< 45 ml/m2.

• Adults ≥18 years old.

• Previous admission for acute heart failure.

• Chronotropic incompetence assessed by CPET, defined as: \[(HRmax - HRrest)\]/\[(220 - age) - (HRrest)\] \< 0.62.

• Resting heart rate \< 65 bpm in sinus rhythm or 70 bmp in atrial fibrillation.

Locations
Other Locations
Spain
Hospital Clínico de la Comunidad Valenciana
RECRUITING
Valencia
Contact Information
Primary
Julio Núñez, Doctor
yulnunez@gmail.es
652856689
Backup
Vicente Bertomeu, Doctor
vbertog@gmail.com
Time Frame
Start Date: 2025-06-17
Estimated Completion Date: 2026-06
Participants
Target number of participants: 30
Treatments
Experimental: Pacing on
Pacemarker stimulation programmed as AAIR / DDDR / VVIR with the basic stimulation frequency and the rate response as follows (pacing on):~* Basic heart rate: derived from the averaged resting heart rates of healthy adults according to height and LVEF.~* Rate response through a combination of minute ventilation and accelerometer: with a response factor of 3 and a medium-low activity threshold.
Placebo_comparator: Pacing off
VVI 30 bpm
Sponsors
Leads: Fundación para la Investigación del Hospital Clínico de Valencia

This content was sourced from clinicaltrials.gov